A new clinical trial for the first time in the world of a cellular immunotherapy for multiple sclerosis (MS) has shown evidence of improving symptoms and quality of life for a large number of patients suffering from this condition. The treatment particularly targets the Epstein-Barr virus (EBV) all thanks to professor Michael Pender a researcher from University of Queensland and Royal Brisbane and Women's Hospital (RBWH). Professor Pender had stated long back in 2003 that multiple sclerosis was the result of accumulation of EBV infected cells in the brain and that a therapy targeting EBV could stop the spread and